TY - JOUR
T1 - Rifampin, rifapentine, and rifabutin are active against intracellular periprosthetic joint infection-associated staphylococcus epidermidis
AU - Fisher, Cody
AU - Patel, Robin
N1 - Funding Information:
MC-3T3-E1 osteoblasts were kindly provided by Jennifer Westendorf (Mayo Clinic Department of Orthopedic Surgery, Rochester, MN), and S. epidermidis 1457 (SE1457) was generously provided by Alexander Horswill (University of Colorado, Department of Immunology and Microbiology, Denver, CO). We also thank Virginia Smith Shapiro and her team (Mayo Clinic Department of Immunology, Rochester, MN) for flow cytometer usage and for lending expertise. C.F. was supported by the Mayo Clinic Initiative for Maximizing Student Development (IMSD) Dean's Fellowship (NIH R25 GM055252 24) and the Ph.D. Training Grant in Basic Immunology (NIH T32 AI07425-25). R.P. was supported by R01 AR056647 and R01 AI091594. R.P. and C.F. designed the experiments. C.F. performed and analyzed the experiments. R.P. supervised C.F. and helped edit and revise the manuscript.
Funding Information:
C.F. was supported by the Mayo Clinic Initiative for Maximizing Student Development (IMSD) Dean’s Fellowship (NIH R25 GM055252 24) and the Ph.D. Training Grant in Basic Immunology (NIH T32 AI07425-25). R.P. was supported by R01 AR056647 and R01 AI091594.
Publisher Copyright:
Copyright © 2021 American Society for Microbiology. All Rights Reserved.
PY - 2021/2
Y1 - 2021/2
N2 - Staphylococcus epidermidis is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant S. epidermidis isolates. Compared to no treatment, treatment resulted in a $2-fold log10 reduction of intracellular rifampin-susceptible, but not rifampin-resistant, S. epidermidis. These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated S. epidermidis.
AB - Staphylococcus epidermidis is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant S. epidermidis isolates. Compared to no treatment, treatment resulted in a $2-fold log10 reduction of intracellular rifampin-susceptible, but not rifampin-resistant, S. epidermidis. These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated S. epidermidis.
KW - Intracellular
KW - Periprosthetic joint infection
KW - Rifamycin
KW - Staphylococcus epidermidis
UR - http://www.scopus.com/inward/record.url?scp=85099978431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099978431&partnerID=8YFLogxK
U2 - 10.1128/AAC.01275-20
DO - 10.1128/AAC.01275-20
M3 - Article
C2 - 33199387
AN - SCOPUS:85099978431
SN - 0066-4804
VL - 65
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 2
M1 - e01275-20
ER -